An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis

References

• Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180–1188.
   PubMed Web of Science ®Google Scholar
• Nicholas R, Rashid W. Multiple sclerosis. BMJ Clin Evid. 2012;2012: 1202.
   PubMedGoogle Scholar
• Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–218.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–1231.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. New Engl J Med. 2000 Sep 28;343:13.
   Web of Science ®Google Scholar
• Diaz-Olavarrieta C, Cummings JL, Velazquez J, et al. Neuropsychiatric manifestations of multiple sclerosis. J Neuropsychiatry Clin Neurosci. 1999;11(1):51–57.
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–558.
   PubMed Web of Science ®Google Scholar
• Fox EJ. Immunopathology of multiple sclerosis. Neurology. 2004;63(12 Suppl 6):S3–7.
   PubMed Web of Science ®Google Scholar
• Hemmer B, Nessler S, Zhou D, et al. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol. 2006;2(4):201–211.
   PubMedGoogle Scholar
• Cappellano G, Comi C, Chiocchetti A, et al. Exploiting PLGA-based biocompatible nanoparticles for next-generation tolerogenic vaccines against autoimmune disease. Int J Mol Sci. 2019;20(1):204.
   PubMed Web of Science ®Google Scholar
• Anderson ME, Siahaan TJ. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides. 2003;24(3):487–501.
   PubMed Web of Science ®Google Scholar
• Falcone M, Rajan AJ, Bloom BR, et al. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J Immunol. 1998;160(10):4822–4830.
   PubMed Web of Science ®Google Scholar
• Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406–419.
   PubMed Web of Science ®Google Scholar
• Ajami B, Bennett JL, Krieger C, et al. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci. 2011;14(9):1142.
   PubMed Web of Science ®Google Scholar
• Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165(2):302–319.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21(1):685–711.
   PubMedGoogle Scholar
• Getts DR, McCarthy DP, Miller SD. Exploiting apoptosis for therapeutic tolerance induction. J Immunol. 2013;191(11):5341–5346.
   PubMed Web of Science ®Google Scholar
• Kuklina EM. Molecular mechanisms of T-cell anergy. Biochem. 2013;78(2):144–156.
   PubMed Web of Science ®Google Scholar
• Getts DR, Turley DM, Smith CE, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10–producing splenic macrophages and maintained by T regulatory cells. J Immunol. 2011;187(5):2405–2417.
   PubMed Web of Science ®Google Scholar
• Pearson RM, Casey LM, Hughes KR, et al. In vivo reprogramming of immune cells: technologies for induction of antigen-specific tolerance. Adv Drug Deliv Rev. 2017;114:240–255.
   PubMed Web of Science ®Google Scholar
• Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005;5(10):772–782.
   PubMed Web of Science ®Google Scholar
• Miller SD, Tan LJ, Pope L, et al. Antigen-specific tolerance as a therapy for experimental autoimmune encephalomyelitis. Int Rev Immunol. 1992;9(3):203–222.
   PubMedGoogle Scholar
• Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716.
   PubMed Web of Science ®Google Scholar
• Mackay IR. Tolerance and autoimmunity. Bmj. 2000;321(7253):93–96.
   PubMedGoogle Scholar
• Bouaziz DJ, Le BH, Saussine A, et al. IL-10 producing regulatory B cells in mice and humans: state of the art. Curr Mol Med. 2012;12(5):519–527.
   PubMed Web of Science ®Google Scholar
• Grant CR, Liberal R, Mieli-Vergani G, et al. Regulatory T-cells in autoimmune diseases: challenges, controversies and—yet—unanswered questions. Autoimmun Rev. 2015;14(2):105–116.
   PubMed Web of Science ®Google Scholar
• Tischner D, Weishaupt A, van Den Brandt J, et al. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain. 2006;129(10):2635–2647.
   PubMedGoogle Scholar
• Bettelli E, Nicholson LB, Kuchroo VK. IL-10, a key effector regulatory cytokine in experimental autoimmune encephalomyelitis. J Autoimmun. 2003;20(4):265.
   PubMed Web of Science ®Google Scholar
• Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat Immunol. 2018;19(7):665–673.
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944.
   PubMed Web of Science ®Google Scholar
• Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005;366(9485):579–582.
   PubMed Web of Science ®Google Scholar
• Wekerle H. B cells in multiple sclerosis. Autoimmunity. 2017;50(1):57–60.
   PubMed Web of Science ®Google Scholar
• Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018;19(7):696–707.
   PubMed Web of Science ®Google Scholar
• Kuo R, Saito E, Miller SD, et al. Peptide-conjugated nanoparticles reduce positive co-stimulatory expression and T cell activity to induce tolerance. Mol Ther. 2017;25(7):1676–1685.
   PubMed Web of Science ®Google Scholar
• Sang Q-X, Muroski ME, Roycik MD, et al. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol. 2008;9(1):34–46.
   PubMed Web of Science ®Google Scholar
• Chaturvedi M, Figiel I, Sreedhar B, et al. Neuroprotection from tissue inhibitor of metalloproteinase-1 and its nanoparticles. Neurochem Int. 2012;61(7):1065–1071.
   PubMed Web of Science ®Google Scholar
• Yeste A, Takenaka MC, Mascanfroni ID, et al. Tolerogenic nanoparticles inhibit T cell–mediated autoimmunity through SOCS2. Sci Signal. 2016;9(433):ra61–ra61.
   PubMed Web of Science ®Google Scholar
• Sfg Z-P, Chiuso-Minicucci F, Tgd F, et al. Persistent Inflammation in the CNS during Chronic EAE Despite Local Absence of IL-17 Production. Teeling J, editor. Mediators Inflamm. 2013;2013:519627.
   PubMed Web of Science ®Google Scholar
• Gharagozloo M, Majewski S, Foldvari M. Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction. Nanomedicine Nanotechnology, Biol Med. 2015;11(4):1003–1018.
   PubMed Web of Science ®Google Scholar
• Yuan B, Zhao L, Fu F, et al. A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis. Mol Immunol. 2014;57(2):93–99.
   PubMed Web of Science ®Google Scholar
• Yeste A, Nadeau M, Burns EJ, et al. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci. 2012;109(28):11270–11275.
   PubMed Web of Science ®Google Scholar
• Quintana FJ. Nanoparticles for the induction of antigen-specific Tregs. Immunotherapy. 2013;5(5):437–440.
   PubMed Web of Science ®Google Scholar
• Carambia A, Freund B, Schwinge D, et al. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. J Hepatol. 2015;62(6):1349–1356.
   PubMed Web of Science ®Google Scholar
• You Q, Cheng L, Kedl RM, et al. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology. 2008;48(3):978–990.
   PubMed Web of Science ®Google Scholar
• Turley DM, Miller SD. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol. 2007;178(4):2212–2220.
   PubMed Web of Science ®Google Scholar
• Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10(11):753.
   PubMed Web of Science ®Google Scholar
• Knolle PA, Schmitt E, Jin S, et al. Induction of cytokine production in naive CD4+ T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology. 1999;116(6):1428–1440.
   PubMed Web of Science ®Google Scholar
• Rosenblum MD, Gratz IK, Paw JS, et al. Treating human autoimmunity: current practice and future prospects. Sci Transl Med. 2012;4(125):125sr1–125sr1.
   PubMed Web of Science ®Google Scholar
• Kipp M, Nyamoya S, Hochstrasser T, et al. Multiple sclerosis animal models: a clinical and histopathological perspective. Brain Pathol. 2017;27(2):123–137.
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Farooqi N, O’Brien K, et al. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164(4):1079–1106.
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bradl M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 2017;133(2):223–244.
   PubMed Web of Science ®Google Scholar
• Hernández-Pedro NY, Espinosa-Ramirez G, De La Cruz VP, et al. Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol. 2013;2013:413465.
   PubMedGoogle Scholar
• Jacobs AH, Tavitian B, Inm C. Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab. 2012;32(7):1393–1415.
   PubMed Web of Science ®Google Scholar
• Cappellano G, Woldetsadik AD, Orilieri E, et al. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis. Vaccine. 2014;32(43):5681–5689.
   PubMed Web of Science ®Google Scholar
• Göbel K, Ruck T, Meuth SG. Cytokine signaling in multiple sclerosis: lost in translation. Mult Scler J. 2018;24(4):432–439.
   PubMed Web of Science ®Google Scholar
• Fux M, van Rooijen N, Owens T. Macrophage-independent T cell infiltration to the site of injury-induced brain inflammation. J Neuroimmunol. 2008;203(1):64–72.
   PubMed Web of Science ®Google Scholar
• Farooqi N, Gran B, Constantinescu CS. Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis? J Neurochem. 2010;115(4):829–844.
   PubMed Web of Science ®Google Scholar
• Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol. 2007;7(11):904.
   PubMed Web of Science ®Google Scholar
• Jahan-Abad AJ, Karima S, Shateri S, et al. Serum pro-inflammatory and anti-inflammatory cytokines and the pathogenesis of experimental autoimmune encephalomyelitis. Neuropathology. 2019;40(1): 84–92.
   PubMed Web of Science ®Google Scholar
• Robinson AP, Harp CT, Noronha A, et al. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol. 2014;122:173–189. Elsevier.
   PubMedGoogle Scholar
• Miljkovic D, Stosic-Grujicic S, Markovic M, et al. Strain difference in susceptibility to experimental autoimmune encephalomyelitis between albino oxford and dark agouti rats correlates with disparity in production of IL-17, but not nitric oxide. J Neurosci Res. 2006;84(2):379–388.
   PubMed Web of Science ®Google Scholar
• Kasagi S, Wang D, Zhang P, et al. Combination of apoptotic T cell induction and self-peptide administration for therapy of experimental autoimmune encephalomyelitis. EBioMedicine. 2019;44:50–59.
   PubMed Web of Science ®Google Scholar
• Derdelinckx J, Mansilla MJ, De Laere M, et al. Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. J Neuroinflammation. 2019;16(1):167.
   PubMed Web of Science ®Google Scholar
• Brocke S, Gijbels K, Steinman L. Experimental autoimmune encephalomyelitis in the mouse. In: Cohen , I, and Miller, A. editor. Autoimmune Dis Model. Elsevier; 1994. p. 1–14.
   Google Scholar
• Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opin Pharmacother. 2006;7(sup1):S1–S9.
   PubMed Web of Science ®Google Scholar
• Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129(8):1953–1971.
   PubMedGoogle Scholar
• Gran B, O’Brien K, Fitzgerald D, et al. Experimental autoimmune encephalomyelitis (EAE). In: Galoyan, A., and Besedovsky, H., editor. Handb Neurochem Mol Neurobiol. United States: Springer. 2007;356–377.
   Google Scholar
• Gaillard PJ, Appeldoorn CCM, Rip J, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release. 2012;164(3):364–369.
   PubMed Web of Science ®Google Scholar
• Floris S, Blezer ELA, Schreibelt G, et al. Blood–brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain. 2004;127(3):616–627.
   PubMedGoogle Scholar
• Reichardt HM, Gold R, Lühder F. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert Rev Neurother. 2006;6(11):1657–1670.
   PubMedGoogle Scholar
• Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv. 2013;10(3):285–287.
   PubMed Web of Science ®Google Scholar
• Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci. 2017;7(7):78.
   Web of Science ®Google Scholar
• Arnon R, Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm. 2009;116(11):1443–1449.
   PubMed Web of Science ®Google Scholar
• Schwartz M, Baruch K. Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. J Autoimmun. 2014;54:8–14.
   PubMed Web of Science ®Google Scholar
• Nally FK, De Santi C, McCoy CE. Nanomodulation of macrophages in multiple sclerosis. Cells. 2019;8(6):543.
   Web of Science ®Google Scholar
• Teitelbaum D, Arnon R, Sela M. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci. 1999;96(7):3842–3847.
   PubMed Web of Science ®Google Scholar
• Amedei A, Prisco D, D’elios MM. Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int J Mol Sci. 2012;13(10):13438–13460.
   PubMed Web of Science ®Google Scholar
• Kayhan B, Aharoni R, Arnon R. Glatiramer acetate (Copaxone®) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. Immunol Lett. 2003;88(3):185–192.
   PubMed Web of Science ®Google Scholar
• Wesley S, Hafler DAMultiple Sclerosis. In: Rose , Noel R., and Mackay, Ian R., editors. Autoimmune Dis. United States: Elsevier; 2020. p. 961–986. DOI:https://doi.org/10.1016/B978-0-12-812102-3.00051-8.
   Google Scholar
• Grigoriadis N, Van Pesch V. A basic overview of multiple sclerosis immunopathology. Eur J Neurol. 2015;22:3–13.
   PubMed Web of Science ®Google Scholar
• Turjeman K, Bavli Y, Kizelsztein P, et al. Nano-drugs based on nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases. PLoS One. 2015;10(7):e0130442.
   PubMed Web of Science ®Google Scholar
• Nuzzo D, Picone P. Multiple sclerosis: focus on extracellular and artificial vesicles, nanoparticles as potential therapeutic approaches. Int J Mol Sci. 2021;22(16):8866.
   PubMed Web of Science ®Google Scholar
• Shishir MRI, Karim N, Gowd V, et al. Liposomal delivery of natural product: a promising approach in health research. Trends Food Sci Technol. 2019;85:177–200.
   Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12.
   PubMed Web of Science ®Google Scholar
• Lai F, Fadda AM, Sinico C. Liposomes for brain delivery. Expert Opin Drug Deliv. 2013;10(7):1003–1022.
   PubMed Web of Science ®Google Scholar
• Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115(19):10938–10966.
   PubMed Web of Science ®Google Scholar
• Kim J-S. Liposomal drug delivery system. J Pharm Investig. 2016;46(4):387–392.
   Google Scholar
• Kumar P, Sharma G, Kumar R, et al. Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies. ACS Chem Neurosci. 2017;8(4):860–865.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Peng Z, Es S, et al. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018;270:290–303.
   PubMed Web of Science ®Google Scholar
• Bellettato CM, Scarpa M. Possible strategies to cross the blood–brain barrier. Ital J Pediatr. 2018;44(2):127–133.
   PubMedGoogle Scholar
• Wong KH, Riaz MK, Xie Y, et al. Review of current strategies for delivering Alzheimer’s disease drugs across the blood-brain barrier. Int J Mol Sci. 2019;20(2):381.
   Web of Science ®Google Scholar
• Grabrucker AM, Ruozi B, Belletti D, et al. Nanoparticle transport across the blood brain barrier. Tissue Barriers. 2016;4(1):e1153568.
   PubMed Web of Science ®Google Scholar
• Phelan AM, Lange DG. Ischemia/reperfusion-induced changes in membrane fluidity characteristics of brain capillary endothelial cells and its prevention by liposomal-incorporated superoxide dismutase. Biochim Biophys Acta (BBA)-Biomembranes. 1991;1067(1):97–102.
   PubMedGoogle Scholar
• Salmaso S, Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv. 2013;2013:374252.
   PubMedGoogle Scholar
• van Rooy I, Mastrobattista E, Storm G, et al. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release. 2011;150(1):30–36.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Engelhardt B, Lesley J, et al. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther. 2000;292(3):1048–1052.
   PubMed Web of Science ®Google Scholar
• Dos Santos Rodrigues B, Oue H, Banerjee A, et al. Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection. J Control Release. 2018;286:264–278.
   PubMed Web of Science ®Google Scholar
• Ramsey JD, Flynn NH. Cell-penetrating peptides transport therapeutics into cells. Pharmacol Ther. 2015;154:78–86.
   PubMed Web of Science ®Google Scholar
• Hu W, Metselaar J, Ben L-H, et al. PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS One. 2009;4(1):e4151.
   PubMed Web of Science ®Google Scholar
• Avnir Y, Turjeman K, Tulchinsky D, et al. Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. PLoS One. 2011;6:10.
   Web of Science ®Google Scholar
• Kizelsztein P, Ovadia H, Garbuzenko O, et al. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. J Neuroimmunol. 2009;213(1–2):20–25.
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Banciu M, Metselaar JM, et al. Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer. J Liposome Res. 2006;16(3):185–194.
   PubMed Web of Science ®Google Scholar
• Lee D-H, Rötger C, Appeldoorn CCM, et al. Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;274(1–2):96–101.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Metselaar JM, Wauben MHM, et al. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain. 2003;126(8):1895–1904.
   PubMedGoogle Scholar
• Schmidt J, Metselaar JM, Gold R. Intravenous liposomal prednisolone downregulates in situ TNF-$α$ production by T-cells in experimental autoimmune encephalomyelitis. J Histochem Cytochem. 2003;51(9):1241–1244.
   PubMed Web of Science ®Google Scholar
• Schweingruber N, Haine A, Tiede K, et al. Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J Immunol. 2011;187(8):4310–4318.
   PubMed Web of Science ®Google Scholar
• Platt AM, Mowat AM. Mucosal macrophages and the regulation of immune responses in the intestine. Immunol Lett. 2008;119(1–2):22–31.
   PubMed Web of Science ®Google Scholar
• Crielaard BJ, Lammers T, Morgan ME, et al. Macrophages and liposomes in inflammatory disease: friends or foes? Int J Pharm. 2011;416(2):499–506.
   PubMedGoogle Scholar
• Linker RA, Weller C, Lühder F, et al. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp Neurol. 2008;211(2):397–406.
   PubMed Web of Science ®Google Scholar
• Xu Y, He Z, Li Z, et al. Irgm1 is required for the inflammatory function of M1 macrophage in early experimental autoimmune encephalomyelitis. J Leukoc Biol. 2017;101(2):507–517.
   PubMed Web of Science ®Google Scholar
• Wüst S, van Den Brandt J, Tischner D, et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol. 2008;180(12):8434–8443.
   PubMed Web of Science ®Google Scholar
• Citterio A, La Mantia L, Ciucci G, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;4:CD001331. doi:https://doi.org/10.1002/14651858.CD001331
   Google Scholar
• Jebali A, Karimabad MN, Ahmadi Z, et al. Attenuation of inflammatory response in the EAE model by PEGlated nanoliposome of pistachio oils. J Neuroimmunol. 2020;347:577352.
   PubMed Web of Science ®Google Scholar
• Olusanya TOB, Haj Ahmad RR, Ibegbu DM, et al. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018;23(4):907.
   PubMed Web of Science ®Google Scholar
• Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):1–29.
   PubMedGoogle Scholar
• Kanhai KMS, Zuiker R, Stavrakaki I, et al. Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. Br J Clin Pharmacol. 2018;84(5):1020–1028.
   PubMed Web of Science ®Google Scholar
• Chen W, Li H, Jia Y, et al. In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis. J Autoimmun. 2007;28(1):30–40.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Cassetti A, Canta A, et al. Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis. Mol Pharm. 2009;6(5):1363–1370.
   PubMedGoogle Scholar
• Croxford JL, Triantaphyllopoulos K, Podhajcer OL, et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol. 1998;160(10):5181–5187.
   PubMed Web of Science ®Google Scholar
• Triantaphyllopoulos KA, Croxford JL, Baker D, et al. Cloning and expression of murine IFN$β$ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther. 1998;5(2):253–263.
   PubMed Web of Science ®Google Scholar
• Jia J, Li H, Tai S, et al. Construction and preliminary investigation of a plasmid containing a novel immunotoxin DT390-IL-18 gene for the prevention of murine experimental autoimmune encephalomyelitis. DNA Cell Biol. 2008;27(5):279–285.
   PubMed Web of Science ®Google Scholar
• Jia Y, Li H, Chen W-J, et al. Primary study of the recombinant immunotoxin DT390-mRantes in EAE therapy. Xi bao yu fen zi mian yi xue za zhi= Chinese J Cell Mol Immu. 2007;23(3):236–239.
   PubMedGoogle Scholar
• Lü ML, Li H, Liang WB, et al. Therapeutic effect of a new recombinant immunotoxin mMIP-1alpha-DT390 on experimental autoimmune encephalomyelitis. Nan fang yi ke da xue xue bao= J South Med Univ. 2007;27(6):775–778.
   PubMedGoogle Scholar
• Filion MC, Phillips NC. Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharm. 1998;162(1–2):159–170.
   Google Scholar
• Litzinger DC. Limitations of cationic liposomes for antisense oligonucleotide delivery in vivo. J Liposome Res. 1997;7(1):51–61.
   Google Scholar
• Liu C, Zhang L, Zhu W, et al. Barriers and strategies of cationic liposomes for cancer gene therapy. Mol Ther Clin Dev. 2020;18:751–764.
   PubMed Web of Science ®Google Scholar
• Strejan GH, Gilbert JJ, Louis JS. Effect of treatment with glutaraldehyde-fixed myelin basic protein—liposomes on active induction and passive transfer of experimental allergic encephalomyelitis in Lewis rats. Cell Immunol. 1988;116(1):250–256.
   PubMed Web of Science ®Google Scholar
• Louis JS, Chan EL, Singh B, et al. Suppression of experimental allergic encephalomyelitis in the Lewis rat, by administration of an acylated synthetic peptide of myelin basic protein. J Neuroimmunol. 1997;73(1–2):90–100.
   PubMed Web of Science ®Google Scholar
• Louis JS, Gilbert JJ, Moscarello MA, et al. Chronic-relapsing experimental allergic encephalomyelitis in strain-13 Guinea pigs: cell-mediated immunity and IgG isoelectric focusing in myelin basic protein-liposome-treated and untreated animals. J Neuroimmunol. 1989;21(2–3):137–147.
   PubMed Web of Science ®Google Scholar
• Avrilionis K, Boggs JM. Suppression of experimental allergic encephalomyelitis by the encephalitogenic peptide, in solution or bound to liposomes. J Neuroimmunol. 1991;35(1–3):201–210.
   PubMed Web of Science ®Google Scholar
• Stein CS, Louis JS, Strejan GH. Myelin-liposome protection against experimental autoimmune encephalomyelitis is associated with reduced neuroantigen-specific T-cell-mediated responses. Cell Immunol. 1993;146(1):80–95.
   PubMed Web of Science ®Google Scholar
• Stein CS, Louis JS, Gilbert JJ, et al. Treatment of spinal cord-induced experimental allergic encephalomyelitis in the Lewis rat with liposomes presenting central nervous system antigens. J Neuroimmunol. 1990;28(2):119–130.
   PubMed Web of Science ®Google Scholar
• Boggs JM, Goundalkar A, Doganoglu F, et al. Antigen-targeted liposome-encapsulated methotrexate specifically kills lymphocytes sensitized to the nonapeptide of myelin basic protein. J Neuroimmunol. 1987;17(1):35–48.
   PubMed Web of Science ®Google Scholar
• Belogurov JAA, Zargarova TA, Turobov VI, et al. Suppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46–62: brief definite report. Autoimmunity. 2009;42(4):362–364.
   PubMed Web of Science ®Google Scholar
• Willenborg DO, Higgins TJ. Liposomes containing myelin basic protein (BP) suppress but do not induce allergic encephalomyelitis in Lewis rats. Aust J Exp Biol Med Sci. 1981;59(2):135–141.
   PubMedGoogle Scholar
• Boggs JM. Myelin basic protein: a multifunctional protein. Cell Mol Life Sci C. 2006;63(17):1945–1961.
   PubMed Web of Science ®Google Scholar
• Peschl P, Bradl M, Höftberger R, et al. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017;8:529.
   PubMed Web of Science ®Google Scholar
• Johns TG, Bernard CCA. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. 1999;72(1):1–9.
   PubMed Web of Science ®Google Scholar
• Belogurov AA Jr, Stepanov AV, Smirnov IV, et al. Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J. 2013;27(1):222–231.
   PubMed Web of Science ®Google Scholar
• Stepanov AV, Belogurov AA, Mamedov AE, et al. Therapeutic effect of mbp immunodominant peptides encapsulated in nanovehicles in the development of experimental autoimmune encephalomyelitis in DA rats. Russ J Bioorganic Chem. 2012;38(3):266–273.
   Web of Science ®Google Scholar
• Jones LA, Chin LT, Kruisbeek AM. Acquisition of self-tolerance in T cells is achieved by different mechanisms, operating both inside and outside the thymus. Thymus. 1990;16(3–4):195–206.
   PubMedGoogle Scholar
• Strejan GH, Gilbert JJ, Louis JS. Suppression of chronic-relapsing experimental allergic encephalomyelitis in strain-13 Guinea pigs by administration of liposome-associated myelin basic protein. J Neuroimmunol. 1984;7:27–41.
   PubMed Web of Science ®Google Scholar
• Kenison JE, Jhaveri A, Li Z, et al. Tolerogenic nanoparticles suppress central nervous system inflammation. Proc Natl Acad Sci. 2020;117(50):32017–32028.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Agata K, Takasugi S, et al. New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect. J Control Release. 2021;335:389–397.
   PubMed Web of Science ®Google Scholar
• Fadok VA, Bratton DL, Rose DM, et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 2000;405(6782):85–90.
   PubMed Web of Science ®Google Scholar
• Hoffmann PR, Kench JA, Vondracek A, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol. 2005;174(3):1393–1404.
   PubMed Web of Science ®Google Scholar
• Bogie JFJ, Jorissen W, Mailleux J, et al. Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun. 2013;1(1):43.
   PubMedGoogle Scholar
• Strejan GH, Louis JS. Suppression of experimental allergic encephalomyelitis by MBP-coupled lymphoid cells and by MBP-liposomes: a comparison. Cell Immunol. 1990;127(2):284–298.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Fernandez S, Pujol-Autonell I, Brianso F, et al. Phosphatidylserine-liposomes promote tolerogenic features on dendritic cells in human type 1 diabetes by apoptotic mimicry. Front Immunol. 2018;9:253.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Balu-Iyer SV. Effect of biophysical properties of phosphatidylserine particle on immune tolerance induction toward factor VIII in a hemophilia A mouse model. J Pharm Sci. 2016;105(10):3039–3045.
   PubMed Web of Science ®Google Scholar
• Pujol-Autonell I, Mansilla M-J, Rodriguez-Fernandez S, et al. Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis. Nanomedicine. 2017;12(11):1231–1242.
   PubMed Web of Science ®Google Scholar
• Strejan GH, Percy DH, Louis JS. Suppression of experimental allergic encephalomyelitis in lewis rats treated with myelin basic protein-liposome complexes: clinical, histopathological, and cell-mediated immunity correlates. Cell Immunol. 1984;84(1):171–184.
   PubMed Web of Science ®Google Scholar
• Lutterotti A, Hayward-Koennecke H, Sospedra M, et al. Antigen-specific immune tolerance in multiple sclerosis—promising approaches and how to bring them to patients. Front Immunol. 2021;12:763.
   Web of Science ®Google Scholar
• Zhang Q, Dai X, Zhang H, et al. Recent advances in development of nanomedicines for multiple sclerosis diagnosis. Biomed Mater. 2021;16(2): 024101 .
   PubMed Web of Science ®Google Scholar
• Lomakin Y, Belogurov A, Glagoleva I, et al. Administration of myelin basic protein peptides encapsulated in mannosylated liposomes normalizes level of serum TNF-$\alpha{$}and IL-2 and chemoattractants ccl2 and ccl4 in multiple sclerosis patients. Mediators Inflamm. 2016;2016(4): 1–8. doi:https://doi.org/10.1155/2016/2847232.
   Google Scholar
• Ivanova VV, Khaiboullina SF, Gomzikova MO, et al. Divergent immunomodulation capacity of individual Myelin Peptides—components of liposomal Therapeutic against Multiple sclerosis. Front Immunol. 2017;8:1335.
   PubMed Web of Science ®Google Scholar
• Belogurov A, Zakharov K, Lomakin Y, et al. CD206-targeted liposomal myelin basic protein peptides in patients with multiple sclerosis resistant to first-line disease-modifying therapies: a first-in-human, proof-of-concept dose-escalation study. Neurotherapeutics. 2016;13(4):895–904.
   PubMed Web of Science ®Google Scholar
• Van Rooijen N. Liposomes for targeting of antigens and drugs: immunoadjuvant activity and liposome-mediated depletion of macrophages. J Drug Target. 2008;16(7–8):529–534.
   PubMed Web of Science ®Google Scholar
• Huitinga I, Van Rooijen N, De Groot CJ, et al. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med. 1990;172(4):1025–1033.
   PubMed Web of Science ®Google Scholar
• Van Rooijen NT. The liposome-mediated macrophage ‘suicide’technique. J Immunol Methods. 1989;124(1):1–6.
   PubMed Web of Science ®Google Scholar
• Huitinga I, Ruuls SR, Jung S, et al. Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin Exp Immunol. 1995;100(2):344–351.
   PubMed Web of Science ®Google Scholar
• Tran EH, Hoekstra K, van Rooijen N, et al. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J Immunol. 1998;161(7):3767–3775.
   PubMed Web of Science ®Google Scholar
• Wang L, Li Z, Ciric B, et al. Selective depletion of CD11c+ CD11b+ dendritic cells partially abrogates tolerogenic effects of intravenous MOG in murine EAE. Eur J Immunol. 2016;46(10):2454–2466.
   PubMed Web of Science ®Google Scholar
• Schiedner G, Hertel S, Johnston M, et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther. 2003;7(1):35–43.
   PubMed Web of Science ®Google Scholar
• Alzuguren P, Hervas-Stubbs S, Gonzalez-Aseguinolaza G, et al. Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver. Liver Int. 2015;35(4):1274–1289.
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Bouwens L, Van Rooijen N, et al. The role of kupffer cells in the differentiation process of hepatic natural killer cells. Hepatology. 1995;22(1):283–290.
   PubMed Web of Science ®Google Scholar
• Soderquest K, Powell N, Luci C, et al. Monocytes control natural killer cell differentiation to effector phenotypes. Blood J Am Soc Hematol. 2011;117(17):4511–4518.
   Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science (80-). 2004;303(5665):1818–1822.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–769.
   PubMed Web of Science ®Google Scholar
• Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J. 2012;14(2):303–315.
   PubMed Web of Science ®Google Scholar
• Hua S, De Matos MBC, Metselaar JM, et al. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:790.
   PubMed Web of Science ®Google Scholar